Base Editing of Gamma-Globin Promoters Increases Fetal Hemoglobin in Sickle Cell Disease

The Evolving Landscape of Genetic Cures for Sickle Cell Disease

Sickle cell disease is a monogenic hemoglobinopathy defined by chronic hemolytic anemia and recurrent vaso-occlusive crises, which are painful episodes caused by sickle-shaped red blood cells obstructing the microvasculature [1, 2, 3]. While hydroxyurea remains a standard therapy, its clinical utility is often limited by poor adherence and inadequate prevention of cumulative organ damage [4, 5]. Allogeneic hematopoietic stem cell transplantation, a procedure that replaces a patient's bone marrow with healthy donor cells, provides a curative option but is restricted by the scarcity of human leukocyte antigen matched donors and the risk of graft versus host disease [1, 2]. Recent strategies utilize ex vivo gene editing to induce fetal hemoglobin, a form of hemoglobin typically absent after infancy, by targeting the BCL11A erythroid-specific enhancer or the gamma-globin promoters [6, 7, 8]. A recent phase 1-2 study of risto-cel evaluated a base editing therapy, a technology that chemically converts one DNA base pair into another without causing double-strand breaks. The researchers demonstrated that 31 patients achieved mean fetal hemoglobin levels exceeding 60% and remained free of severe vaso-occlusive crises during follow-up, suggesting a potential pathway to functionally cure the disease without relying on donor availability [9].

Precision Base Editing of the Gamma-Globin Promoters

Risto-cel, also known as ristoglogene autogetemcel, utilizes base editing to specifically target the HBG1 and HBG2 promoters, the DNA sequences that initiate the transcription of gamma-globin genes. Unlike traditional gene editing that creates double-strand breaks in the DNA, base editing chemically alters individual DNA bases. This precise modification is designed to inhibit the binding of BCL11A, a transcription factor that acts as a repressor of fetal hemoglobin production. By disrupting the binding site on the HBG1 and HBG2 promoters, the therapy prevents BCL11A from silencing these genes. Crucially, this mechanism inhibits BCL11A binding without altering the overall expression of the BCL11A protein in other cell types, such as B-lymphocytes, where the protein is essential for normal immune development. For clinicians, this targeted approach minimizes off-target systemic effects while achieving the desired hematologic goal. The molecular objective is to induce a physiological switch in hemoglobin production, transitioning erythroid cells from producing sickle hemoglobin (HbS) to producing antisickling fetal hemoglobin (HbF). In the interim analysis of 31 patients, the researchers found that this approach was highly effective at the genomic level. At 6 months post-infusion, the mean fraction of on-target edited alleles in peripheral blood was 67.4%. This high rate of editing translated directly into altered protein expression. Among 13 patients with at least 6 months of follow-up, the mean fetal hemoglobin (HbF) as a fraction of total hemoglobin was more than 60%, while the sickle hemoglobin (HbS) fraction was reduced to less than 40%. These levels remained stable throughout the follow-up period, which reached a maximum of 20.4 months. Clinical outcomes reflected these biochemical changes, as no investigator-reported severe vaso-occlusive crises occurred later than 60 days after the last red-cell transfusion. The treatment process involved a median of one cycle (range, one to five) for stem-cell collection, followed by a median of 17.5 days for neutrophil engraftment and 19 days for platelet engraftment. While the efficacy data are robust, the safety profile requires careful monitoring. All 31 patients experienced at least one adverse event, with 27 patients (87%) reporting an adverse event of grade 3 or higher and 12 patients (39%) experiencing a serious adverse event. One death occurred due to idiopathic pneumonia syndrome, a non-infectious inflammatory lung injury that can follow hematopoietic cell transplantation.

Trial Design and Stem Cell Collection Metrics

The BEACON study, a phase 1-2 clinical trial, evaluated the safety and efficacy of a single dose of risto-cel in a cohort of 31 patients with sickle cell disease. The treatment protocol required the collection of autologous hematopoietic stem cells, the precursor cells responsible for blood production. The researchers reported that a median of one cycle was necessary for successful stem-cell collection, though the requirement ranged from one to five cycles across the participant group. Following collection and ex vivo base editing, the manufactured product was administered with a target dose ranging from 3.0x10^6 to 10.0x10^6 viable CD34+ cells per kilogram of body weight. CD34 is a well-established surface marker for hematopoietic stem and progenitor cells, and this specific dosing strategy aims to ensure a sufficient population of edited cells to achieve durable engraftment in the bone marrow. To assess the clinical impact of the therapy, the researchers established a primary efficacy end point defined as freedom from severe vaso-occlusive crises for 12 consecutive months. These crises are characterized by acute, debilitating pain resulting from microvascular obstruction and routinely require hospitalization or emergency medical intervention. For the purposes of this trial, the 12-month evaluation period began 60 days after the patient's last red-cell transfusion. This delay ensures that any observed clinical stability is attributable to the newly edited cells rather than residual donor blood. At the time of this interim analysis, the 31 patients had been followed for a mean of 6.6 months, with a follow-up range extending from 0.3 to 20.4 months. These metrics provide a critical baseline for evaluating the long-term durability of fetal hemoglobin induction and its ability to prevent the hallmark complications of the disease in routine clinical practice.

Engraftment Kinetics and Safety Profile

Following the infusion of risto-cel, the researchers monitored the kinetics of hematopoietic recovery to determine how quickly the edited stem cells established functional blood production. The study reported that neutrophil engraftment, which marks the point at which the absolute neutrophil count reaches a level sufficient to protect against opportunistic infections, occurred at a median of 17.5 days. Similarly, platelet engraftment, the time required for the patient to maintain a stable platelet count without relying on transfusions, was achieved at a median of 19 days. These timelines are consistent with standard autologous hematopoietic stem cell transplantation protocols. For practicing hematologists, this indicates that the ex vivo base editing process did not significantly impair the repopulating capacity of the CD34+ progenitor cells. The safety analysis of the 31 participants revealed a high incidence of complications, an expected outcome given the intensive myeloablative conditioning regimens required to prepare the bone marrow for stem cell therapies. All 31 patients (100%) experienced at least one adverse event during the study period. More severe complications were frequent, with 27 patients (87%) reporting an adverse event of grade 3 or higher, indicating severe or medically significant conditions. Furthermore, 12 patients (39%) experienced a serious adverse event, defined as any untoward medical occurrence that results in death, is life-threatening, or requires hospitalization. Notably, one patient died from idiopathic pneumonia syndrome, a severe form of non-infectious, diffuse lung injury that is a known complication following hematopoietic stem cell transplantation. Despite these inherent risks, the researchers noted that the majority of adverse events were manageable and aligned with the established toxicity profile of myeloablative conditioning.

Durable Hemoglobin Switching and Clinical Outcomes

The ultimate efficacy of risto-cel depends on the successful modification of hematopoietic stem cells to ensure a permanent shift in hemoglobin production. At the 6-month mark, the researchers found that the mean fraction of on-target edited alleles in peripheral blood was 67.4%, indicating high efficiency in the base editing process across the patient cohort. This genetic modification translated directly into a significant alteration of the erythroid phenotype. Among the 13 patients evaluable at 6 months, the mean fetal hemoglobin (HbF) as a fraction of total hemoglobin was more than 60%, while the sickle hemoglobin (HbS) as a fraction of total hemoglobin was reduced to less than 40%. These quantitative shifts are highly relevant for daily clinical practice, as elevated levels of fetal hemoglobin directly interfere with the polymerization of sickle hemoglobin, the primary driver of red blood cell sickling and subsequent vaso-occlusion. Longitudinal monitoring demonstrated that these biochemical changes were not transient. The researchers observed that hemoglobin levels, specifically the high fraction of HbF and the reduced fraction of HbS, were maintained throughout the follow-up period, which extended up to 20.4 months for some participants. This durability suggests that the edited progenitor cells successfully established long-term hematopoiesis. Most importantly, these laboratory results correlated with a complete resolution of the most debilitating clinical manifestations of the disease. During the study, no investigator-reported severe vaso-occlusive crises occurred later than 60 days after the last red-cell transfusion. This complete absence of severe pain crises and organ-threatening ischemic events suggests that achieving a fetal hemoglobin threshold of 60% through base editing may provide a robust, long-lasting clinical defense against the hallmark complications of sickle cell disease.

References

1. Arebee AS. CRISPR Gene-Editing Therapies for Sickle Cell Disease and Beta- Thalassemia: Clinical Outcomes, Risks and Safety Profiles. A Systematic Review. 2025. doi:10.64943/ljmas.v3i4.254

2. Desai K, Croce P, Dadhania N, et al. CRISPR Cas-9 Editing for Treating Sickle Cell Disease: A Systematic Review and Meta-Analysis. Blood. 2024. doi:10.1182/blood-2024-204091

3. Mahesri M, Lee SB, Levin R, et al. Infrequent Resolution of Vaso‐Occlusive Crises in Routine Clinical Care Among Patients Mimicking the Exa‐Cel Trial Population: A Cohort Study of Medicaid Enrollees. Clinical pharmacology and therapy. 2024. doi:10.1002/cpt.3449

4. Sins JWR, Mager D, Davis SC, Biemond BJ, Fijnvandraat K. Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. Blood Advances. 2017. doi:10.1182/bloodadvances.2017007211

5. Ryan N, Dike L, Ojo T, et al. Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability. BMJ Open. 2020. doi:10.1136/bmjopen-2020-038685

6. Gab-Obinna C, Oriaku I, Okeoma OI, et al. Gene Editing Therapies for Sickle Cell Disease and β-Thalassemia: A Systematic Review of Clinical Outcomes and Safety. 2026. doi:10.63946/aubiomed/17736

7. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. New England Journal of Medicine. 2020. doi:10.1056/nejmoa2031054

8. Quagliano A, Acevedo D, Hardigan P, Prasad S. Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in β-thalassemia and sickle cell disease: A comparative meta-analysis. Frontiers in Medicine. 2022. doi:10.3389/fmed.2022.943631

9. Gupta AO, Sharma A, Frangoul H, et al. Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.. The New England journal of medicine. 2026. doi:10.1056/NEJMoa2504835